[病例报告:子宫颈腺癌后冷冻卵巢组织异位再移植]。

Markus Lipovac, Julia Herzog, Martin Imhof
{"title":"[病例报告:子宫颈腺癌后冷冻卵巢组织异位再移植]。","authors":"Markus Lipovac,&nbsp;Julia Herzog,&nbsp;Martin Imhof","doi":"10.1007/s41974-020-00160-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Retransplantation of cryopreserved ovarian tissue has become an established method of restoring autologous hormone production and fertility after radiotherapy and/or chemotherapy for underlying oncological disease in women of reproductive age and has so far led to more than 170 births worldwide.</p><p><strong>Case presentation and course: </strong>In 2013, the 31-year-old patient developed adenocarcinoma of the uterine cervix, pT1b1V0L0. In January 2014, an extended hysterectomy with lymph node dissection and bilateral adnexectomy were performed. At the patient's request, ovarian tissue was cryopreserved 2 days previously. In November 2019, the retransplantation of two ovarian tissue pieces along the brachial fascia of the left forearm was performed, with no recurrence for 5 years under ongoing hormone replacement therapy (HRT). At 1 month following retransplantation, the patient stopped taking HRT, and 3 months later proper function of the retransplanted tissue could be demonstrated by checking gonadotropins and E2 levels. There was a clear swelling in the area of the retransplantation site, and three vital follicles could be visualized during an ultrasound examination in May 2020.</p><p><strong>Conclusion: </strong>This is the first successful retransplantation of cryopreserved ovarian tissue to restore autologous hormone production in a cervical cancer patient in Austria. Based on blood, ultrasound and cytological examinations, not to mention the patient's personal well-being, functionality of the retransplanted tissue could be demonstrated even at 6 months after the procedure. Finally, the authors would like to highlight the importance of informing and consulting young patients with tumor diseases on the various possibilities of fertility preservation.</p>","PeriodicalId":40002,"journal":{"name":"Journal fur Gynakologische Endokrinologie","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s41974-020-00160-w","citationCount":"0","resultStr":"{\"title\":\"[Case Report: Heterotopic Retransplantation of Cryopreserved Ovarian Tissue after Adenocarcinoma of the Uterine Cervix].\",\"authors\":\"Markus Lipovac,&nbsp;Julia Herzog,&nbsp;Martin Imhof\",\"doi\":\"10.1007/s41974-020-00160-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Retransplantation of cryopreserved ovarian tissue has become an established method of restoring autologous hormone production and fertility after radiotherapy and/or chemotherapy for underlying oncological disease in women of reproductive age and has so far led to more than 170 births worldwide.</p><p><strong>Case presentation and course: </strong>In 2013, the 31-year-old patient developed adenocarcinoma of the uterine cervix, pT1b1V0L0. In January 2014, an extended hysterectomy with lymph node dissection and bilateral adnexectomy were performed. At the patient's request, ovarian tissue was cryopreserved 2 days previously. In November 2019, the retransplantation of two ovarian tissue pieces along the brachial fascia of the left forearm was performed, with no recurrence for 5 years under ongoing hormone replacement therapy (HRT). At 1 month following retransplantation, the patient stopped taking HRT, and 3 months later proper function of the retransplanted tissue could be demonstrated by checking gonadotropins and E2 levels. There was a clear swelling in the area of the retransplantation site, and three vital follicles could be visualized during an ultrasound examination in May 2020.</p><p><strong>Conclusion: </strong>This is the first successful retransplantation of cryopreserved ovarian tissue to restore autologous hormone production in a cervical cancer patient in Austria. Based on blood, ultrasound and cytological examinations, not to mention the patient's personal well-being, functionality of the retransplanted tissue could be demonstrated even at 6 months after the procedure. Finally, the authors would like to highlight the importance of informing and consulting young patients with tumor diseases on the various possibilities of fertility preservation.</p>\",\"PeriodicalId\":40002,\"journal\":{\"name\":\"Journal fur Gynakologische Endokrinologie\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s41974-020-00160-w\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal fur Gynakologische Endokrinologie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s41974-020-00160-w\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/10/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal fur Gynakologische Endokrinologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s41974-020-00160-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/10/14 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

引言:冷冻保存的卵巢组织再移植已成为育龄妇女治疗潜在肿瘤疾病放疗和/或化疗后恢复自身激素产生和生育能力的一种既定方法,迄今已在全球范围内导致170多例分娩。病例介绍及病程:2013年,31岁患者发生子宫颈腺癌pT1b1V0L0。2014年1月行扩大子宫切除术合并淋巴结清扫和双侧附件切除术。应患者要求,卵巢组织在2天前冷冻保存。2019年11月,沿左前臂肱筋膜进行了两次卵巢组织块再移植,在持续的激素替代治疗(HRT)下,5年未复发。再移植后1个月,患者停止使用HRT, 3个月后,通过检测促性腺激素和E2水平可以证明再移植组织功能正常。再移植部位明显肿胀,2020年5月超声检查时可见三个重要卵泡。结论:这是奥地利宫颈癌患者首次成功的冷冻卵巢组织再移植以恢复自体激素的产生。根据血液、超声和细胞学检查,更不用说患者的个人健康状况,即使在手术后6个月,也可以证明再移植组织的功能。最后,作者想强调告知和咨询年轻肿瘤患者保留生育能力的各种可能性的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

[Case Report: Heterotopic Retransplantation of Cryopreserved Ovarian Tissue after Adenocarcinoma of the Uterine Cervix].

[Case Report: Heterotopic Retransplantation of Cryopreserved Ovarian Tissue after Adenocarcinoma of the Uterine Cervix].

[Case Report: Heterotopic Retransplantation of Cryopreserved Ovarian Tissue after Adenocarcinoma of the Uterine Cervix].

Introduction: Retransplantation of cryopreserved ovarian tissue has become an established method of restoring autologous hormone production and fertility after radiotherapy and/or chemotherapy for underlying oncological disease in women of reproductive age and has so far led to more than 170 births worldwide.

Case presentation and course: In 2013, the 31-year-old patient developed adenocarcinoma of the uterine cervix, pT1b1V0L0. In January 2014, an extended hysterectomy with lymph node dissection and bilateral adnexectomy were performed. At the patient's request, ovarian tissue was cryopreserved 2 days previously. In November 2019, the retransplantation of two ovarian tissue pieces along the brachial fascia of the left forearm was performed, with no recurrence for 5 years under ongoing hormone replacement therapy (HRT). At 1 month following retransplantation, the patient stopped taking HRT, and 3 months later proper function of the retransplanted tissue could be demonstrated by checking gonadotropins and E2 levels. There was a clear swelling in the area of the retransplantation site, and three vital follicles could be visualized during an ultrasound examination in May 2020.

Conclusion: This is the first successful retransplantation of cryopreserved ovarian tissue to restore autologous hormone production in a cervical cancer patient in Austria. Based on blood, ultrasound and cytological examinations, not to mention the patient's personal well-being, functionality of the retransplanted tissue could be demonstrated even at 6 months after the procedure. Finally, the authors would like to highlight the importance of informing and consulting young patients with tumor diseases on the various possibilities of fertility preservation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal fur Gynakologische Endokrinologie
Journal fur Gynakologische Endokrinologie Medicine-Obstetrics and Gynecology
CiteScore
0.20
自引率
0.00%
发文量
33
期刊介绍: Das Journal für Gynäkologische Endokrinologie veröffentlicht Originalarbeiten, Übersichten, Fallberichte, Kurzberichte sowie Kommentare aus allen Bereichen, die Assistierte Reproduktion, Kontrazeption und Menopause betreffen. Experimentelle Untersuchungen sollten einen direkten klinischen Bezug aufweisen. Das Journal versteht sich als praxisorientiertes Fortbildungsmagazin und möchte Aktualität und Wissen vermitteln. Namhafte Expert*innen kommen zu Wort und beleuchten Schwerpunkte des Praxisalltags. Dadurch soll die Einbindung neuester Erkenntnisse in die tägliche Routinearbeit erleichtert werden.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信